Taysha Q3 net loss $117.1M on warrant expense; TSHA-102 well-tolerated with clinical improvements

Taysha Gene Therapies, Inc.

2023-Q3 EPS reported -$1.88 revenue$11,847,000

Net loss $117.1M ($0.93/shr) includes $100.5M non-cash fair value change in warrant liability; prior year net loss $26.5M.
Cash and cash equivalents $164.3M; runway extended into 2026 via new loan with Trinity Capital (no financial covenants or warrants).
TSHA-102 first two adult patients: well-tolerated, no SAEs; sustained improvements in autonomic, motor, socialization functions at week 12 (patient 1) and week 4 (patient 2).
IDMC cleared dosing of third adult patient; low-dose cohort completion and first U.S. pediatric dosing expected Q1 2024.
R&D expenses $11.8M (down from $16.8M YoY) due to lower headcount and licensing fees, partially offset by clinical trial costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Taysha Gene Therapies, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

View on SEC.gov

Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-277165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.